These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 25211926)

  • 21. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M; Kudoh J; Homma Y; Kawabe K
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability.
    Lepor H; Hill LA
    Pharmacotherapy; 2010 Dec; 30(12):1303-12. PubMed ID: 21114397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Osman NI; Chapple CR; Cruz F; Desgrandchamps F; Llorente C; Montorsi F
    Expert Opin Pharmacother; 2012 Oct; 13(14):2085-96. PubMed ID: 22924980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experience of the use of drug urorec: efficacy and safety].
    Kadiev RM; Derevianko TI
    Urologiia; 2014; (3):44, 46-7. PubMed ID: 25211926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
    Capitanio U; Salonia A; Briganti A; Montorsi F
    Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
    Schilit S; Benzeroual KE
    Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silodosin for benign prostatic hyperplasia.
    Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
    Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. α-Blockers for benign prostatic hyperplasia: the new era.
    Lepor H; Kazzazi A; Djavan B
    Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Profile of silodosin].
    Montorsi F
    Urologiia; 2013; (2):112-4, 116-7. PubMed ID: 23789376
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.